ResearchMoz

PharmaPoint: Migraine US and 5EU Drug Forecast and Market Analysis to 2023

Researchmoz presents this most up-to-date research on"PharmaPoint: Migraine US and 5EU Drug Forecast and Market Analysis to 2023". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

 

Albany, NY -- (ReleaseWire) -- 04/22/2014 -- ResearchMoz.us include new market research report"PharmaPoint: Migraine US and 5EU Drug Forecast and Market Analysis to 2023"to its huge collection of research reports.

PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023 http://www.researchmoz.us/pharmapoint-migraine-us-drug-forecast-and-market-analysis-to-2023-report.html

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergans Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSKs Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan.

Browse Healthcare Related Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Scope
Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the US from 2012-2023.

Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market.

PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023 http://www.researchmoz.us/pharmapoint-migraine-5eu-drug-forecast-and-market-analysis-to-2023-report.html

By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Each of the countries included in this report provide guidelines for the treatment of migraine. According to GlobalDatas high-prescriber survey, the US, UK and Japan strongly adhere to their own national guidelines; however, the majority of the physicians from other EU countries (France, Germany, Italy and Spain) follow European guidelines such as the European Headache Federation (EHF) and European Federation of Neurological Societies (EFNS) guidelines.

Scope
Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2012-2023.

Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market.

For More Information Kindly Contact:
Email: http://www.sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://globalandchinamarket.blogspot.com
word press : http://marketresearchtopix.wordpress.com